BIOMAT Database Logo BIOMAT Database Logo

A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia. 2019

Ronja Bjørnstad, and Reidun Aesoy, and Øystein Bruserud, and Annette K Brenner, and Francis Giraud, and Tara Helen Dowling, and Gro Gausdal, and Pascale Moreau, and Stein Ove Døskeland, and Fabrice Anizon, and Lars Herfindal
Department of Clinical Science, Centre for Pharmacy, University of Bergen, Bergen, Norway.

More than 40 years ago, the present standard induction therapy for acute myeloid leukemia (AML) was developed. This consists of the metabolic inhibitor cytarabine (AraC) and the cytostatic topoisomerase 2 inhibitor daunorubucin (DNR). In light of the high chance for relapse, as well as the large heterogeneity, novel therapies are needed to improve patient outcome. We have tested the anti-AML activity of 15 novel compounds based on the scaffolds pyrrolo[2,3-a]carbazole-3-carbaldehyde, pyrazolo[3,4-c]carbazole, pyrazolo[4,3-a]phenanthridine, or pyrrolo[2,3-g]indazole. The compounds were inhibitors of Pim kinases, but could also have inhibitory activity against other protein kinases. Ser/Thr kinases like the Pim kinases have been identified as potential drug targets for AML therapy. The compound VS-II-173 induced AML cell death with EC50 below 5 μmol/L, and was 10 times less potent against nonmalignant cells. It perturbed Pim-kinase-mediated AML cell signaling, such as attenuation of Stat5 or MDM2 phosphorylation, and synergized with DNR to induce AML cell death. VS-II-173 induced cell death also in patients with AML blasts, including blast carrying high-risk FLT3-ITD mutations. Mutation of nucleophosmin-1 was associated with good response to VS-II-173. In conclusion new scaffolds for potential AML drugs have been explored. The selective activity toward patient AML blasts and AML cell lines of the pyrazolo-analogue VS-II-173 make it a promising drug candidate to be further tested in preclinical animal models for AML.

UI MeSH Term Description Entries
D007191 Indazoles A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES. Indazole
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D002227 Carbazoles Benzo-indoles similar to CARBOLINES which are pyrido-indoles. In plants, carbazoles are derived from indole and form some of the INDOLE ALKALOIDS.
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D015470 Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Leukemia, Myelogenous, Acute,Leukemia, Nonlymphocytic, Acute,Myeloid Leukemia, Acute,Nonlymphocytic Leukemia, Acute,ANLL,Acute Myelogenous Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with Maturation,Acute Myeloid Leukemia without Maturation,Leukemia, Acute Myelogenous,Leukemia, Acute Myeloid,Leukemia, Myeloblastic, Acute,Leukemia, Myelocytic, Acute,Leukemia, Myeloid, Acute, M1,Leukemia, Myeloid, Acute, M2,Leukemia, Nonlymphoblastic, Acute,Myeloblastic Leukemia, Acute,Myelocytic Leukemia, Acute,Myelogenous Leukemia, Acute,Myeloid Leukemia, Acute, M1,Myeloid Leukemia, Acute, M2,Nonlymphoblastic Leukemia, Acute,Acute Myeloblastic Leukemia,Acute Myeloblastic Leukemias,Acute Myelocytic Leukemia,Acute Myelocytic Leukemias,Acute Myelogenous Leukemias,Acute Myeloid Leukemias,Acute Nonlymphoblastic Leukemia,Acute Nonlymphoblastic Leukemias,Acute Nonlymphocytic Leukemia,Acute Nonlymphocytic Leukemias,Leukemia, Acute Myeloblastic,Leukemia, Acute Myelocytic,Leukemia, Acute Nonlymphoblastic,Leukemia, Acute Nonlymphocytic,Leukemias, Acute Myeloblastic,Leukemias, Acute Myelocytic,Leukemias, Acute Myelogenous,Leukemias, Acute Myeloid,Leukemias, Acute Nonlymphoblastic,Leukemias, Acute Nonlymphocytic,Myeloblastic Leukemias, Acute,Myelocytic Leukemias, Acute,Myelogenous Leukemias, Acute,Myeloid Leukemias, Acute,Nonlymphoblastic Leukemias, Acute,Nonlymphocytic Leukemias, Acute
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines

Related Publications

Ronja Bjørnstad, and Reidun Aesoy, and Øystein Bruserud, and Annette K Brenner, and Francis Giraud, and Tara Helen Dowling, and Gro Gausdal, and Pascale Moreau, and Stein Ove Døskeland, and Fabrice Anizon, and Lars Herfindal
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.
February 2014, Blood,
Ronja Bjørnstad, and Reidun Aesoy, and Øystein Bruserud, and Annette K Brenner, and Francis Giraud, and Tara Helen Dowling, and Gro Gausdal, and Pascale Moreau, and Stein Ove Døskeland, and Fabrice Anizon, and Lars Herfindal
Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.
July 2011, Blood,
Ronja Bjørnstad, and Reidun Aesoy, and Øystein Bruserud, and Annette K Brenner, and Francis Giraud, and Tara Helen Dowling, and Gro Gausdal, and Pascale Moreau, and Stein Ove Døskeland, and Fabrice Anizon, and Lars Herfindal
Mebendazole exhibits potent anti-leukemia activity on acute myeloid leukemia.
August 2018, Experimental cell research,
Ronja Bjørnstad, and Reidun Aesoy, and Øystein Bruserud, and Annette K Brenner, and Francis Giraud, and Tara Helen Dowling, and Gro Gausdal, and Pascale Moreau, and Stein Ove Døskeland, and Fabrice Anizon, and Lars Herfindal
The Tumor-Selective Cytotoxic Agent β-Lapachone is a Potent Inhibitor of IDO1.
January 2013, International journal of tryptophan research : IJTR,
Ronja Bjørnstad, and Reidun Aesoy, and Øystein Bruserud, and Annette K Brenner, and Francis Giraud, and Tara Helen Dowling, and Gro Gausdal, and Pascale Moreau, and Stein Ove Døskeland, and Fabrice Anizon, and Lars Herfindal
Preclinical evaluation of WYE-687, a mTOR kinase inhibitor, as a potential anti-acute myeloid leukemia agent.
February 2016, Biochemical and biophysical research communications,
Ronja Bjørnstad, and Reidun Aesoy, and Øystein Bruserud, and Annette K Brenner, and Francis Giraud, and Tara Helen Dowling, and Gro Gausdal, and Pascale Moreau, and Stein Ove Døskeland, and Fabrice Anizon, and Lars Herfindal
Discovery of a high potent PIM kinase inhibitor for acute myeloid leukemia based on N-pyridinyl amide scaffold by optimizing the fragments toward to Lys67 and Asp128/Glu171.
September 2023, European journal of medicinal chemistry,
Ronja Bjørnstad, and Reidun Aesoy, and Øystein Bruserud, and Annette K Brenner, and Francis Giraud, and Tara Helen Dowling, and Gro Gausdal, and Pascale Moreau, and Stein Ove Døskeland, and Fabrice Anizon, and Lars Herfindal
Oral, anti-inflammatory activity of a potent, selective, protein kinase C inhibitor.
September 1992, Agents and actions,
Ronja Bjørnstad, and Reidun Aesoy, and Øystein Bruserud, and Annette K Brenner, and Francis Giraud, and Tara Helen Dowling, and Gro Gausdal, and Pascale Moreau, and Stein Ove Døskeland, and Fabrice Anizon, and Lars Herfindal
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
October 2009, Blood,
Ronja Bjørnstad, and Reidun Aesoy, and Øystein Bruserud, and Annette K Brenner, and Francis Giraud, and Tara Helen Dowling, and Gro Gausdal, and Pascale Moreau, and Stein Ove Døskeland, and Fabrice Anizon, and Lars Herfindal
Discovery of a potent and selective CBP bromodomain inhibitor (Y08262) for treating acute myeloid leukemia.
January 2024, Bioorganic chemistry,
Ronja Bjørnstad, and Reidun Aesoy, and Øystein Bruserud, and Annette K Brenner, and Francis Giraud, and Tara Helen Dowling, and Gro Gausdal, and Pascale Moreau, and Stein Ove Døskeland, and Fabrice Anizon, and Lars Herfindal
Gö6976, a FLT3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and MCL-1.
July 2014, Biochemical pharmacology,
Copied contents to your clipboard!